Optic disc edema as a possible complication of Imatinib mesylate (Gleevec)

Jpn J Ophthalmol. 2008 Jul-Aug;52(4):331-333. doi: 10.1007/s10384-008-0561-7. Epub 2008 Sep 5.

Abstract

Background: Imatinib is effective for a variety of hematologic and nonhematologic malignancies. Well-known ocular side effects are periorbital edema, epiphora, extraocular muscle palsy, and blepharoconjunctivitis. However, optic disc edema has not been reported as a complication of imatinib mesylate. Herein, we describe a patient with chronic myeloid leukemia (CML) who developed optic disc edema during treatment with imatinib.

Case: A 14-year-old Korean girl was referred to ophthalmology for a 3-week history of photopsia in both eyes. She had started taking imatinib daily 2 months previously for CML. At the initial exam, slit lamp showed optic disc edema in both eyes, even though visual acuity was 20/20 and other optic nerve function evaluations were within normal limits. We recommended to the oncologist discontinuation of the imatinib treatment.

Observations: When the patient was followed for 1 week after stopping imatinib treatment, the frequency of photopsia decreased and the optic disc edema improved. Because a second examination 3 weeks after discontinuation of imatinib revealed much improved optic disc edema, she restarted the imatinib treatment. No ocular side effects have been noted so far.

Conclusions: Optic disc edema should be considered one of the complications associated with imatinib. We propose discontinuation of the treatment for a short period when optic disc edema occurs.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents / adverse effects*
  • Benzamides
  • Female
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Optic Disk / drug effects*
  • Optic Disk / physiopathology
  • Papilledema / chemically induced*
  • Papilledema / physiopathology
  • Piperazines / adverse effects*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / adverse effects*
  • Tomography, Optical Coherence
  • Visual Acuity

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases